Clinical trials: Anlotinib
Extensive Stage Small Cell Lung Cancer
A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC
This is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of tislelizumab combined with Anlotinib as maintenance therapy following tislelizumab and chemotherapy for treatment naïve extensive…
- Trial name
- NCT05896059
- Testing
- Tislelizumab, Anlotinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhejiang Cancer Hospital
Pheochromocytoma, Paraganglioma
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL
This phase II trial studies the effectiveness of anlotinib hydrochloride in the neoadjuvant therapy of locally advanced, or unresectable pheochromocytoma or paragangliom(PPGL).
- Trial name
- NCT05883085
- Testing
- Anlotinib hydrochloride
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Esophageal Cancer
Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer
The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma who failed Standard first line therapy.
- Trial name
- NCT05866510
- Testing
- Utidelone and anlotinib
- Where
- 3 sites in China
- Volunteers
- 47 people
- Sponsor
- Peking University
Esophageal Squamous Cell Carcinoma
Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC)
To evaluate the effectiveness and safety of anlotinib combined with TQB2450 (PD-L1 inhibitor) in the first-line treatment of patients with advanced ESCC.
- Trial name
- NCT05038813
- Testing
- Anlotinib+TQB2450
- Where
- 5 sites in China
- Volunteers
- 46 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Hepatocellular Carcinoma
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
The primary objective of this study was to evaluate the efficacy of anlotinib hydrochloride capsules combined with penpulimab injection (test group) versus placebo (control group) for adjuvant therapy after radical surgery or…
- Trial name
- NCT05862337
- Testing
- Anlotinib hydrochloride capsules, Penpulimab injection
- Where
- 67 sites in China
- Volunteers
- 480 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Retroperitoneal Sarcoma
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma
The goal of this clinical trial is to explore the potential survival benefits of neoadjuvant chemotherapy combined with target treatments followed by radical surgery in patients with primary high-risk/grade retroperitoneal…
- Trial name
- NATARS (NCT05844813)
- Testing
- Doxorubicin+Ifosfamide+Anlotinib(AI+A), Radical Surgery
- Where
- 6 sites in China
- Volunteers
- 102 people
- Sponsor
- Peking University International Hospital
Platinum-resistant Ovarian Cancer
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
The goal of this clinical trial is to evaluate the treatment of topotecan hydrochloride capsules combined with anlotinib hydrochloride capsules in Patients with platinum-resistant recurrent epithelial ovarian cancer.
- Trial name
- NCT05736952
- Testing
- Oral Topotecan Combined With Anlotinib
- Where
- China
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Non Small Cell Lung Cancer Recurrent
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
This is a phase II, single arm, open-label, single-center study to evaluate the efficacy and safety of Toripalimab combined with Chemotherapy and Antiangiogenic Agents in patients with Non-Small Cell Lung Cancer After Failure of…
- Trial name
- NCT05842018
- Testing
- Toripalimab, Anlotinib and Chemotherapy
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer (NSCLC)
First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations
This is a multicenter, open label, Phase I/IIB study investigating the efficacy and safety of treatment with dacomitinib plus anlotinib as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) with…
- Trial name
- NCT05271916
- Testing
- Dacomitinib+Anlotinib, Dacomitinib
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Shanghai Chest Hospital
Gastric Cancer
An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGC
1. Main objective: to evaluate the pathological complete response (pCR) of gastric cancer after local advanced COVID-19 infection by two kinds of immunotherapy combined with Anlotinib Hydrochloride Capsules and neoadjuvant…
- Trial name
- NCT05800080
- Testing
- Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Xijing Hospital
Overall Survival
Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer
This research study is a Phase 2 clinical trial. It will test the efficiency and safety of an investigational drug of Anlotinib (a small molecular anti-VEGF TKI) with PD-1 inhibitor in second-line therapy with the goal of…
- Trial name
- NCT05218629
- Testing
- Anlotinib, PD-1 inhibitor
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Qingdao Central Hospital
Aumolertinib, Anlotinib
Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation
The goal of this open, single-arm, exploratory phase II clinical study is to exploratory safety and efficacy in 1st line treatment in advanced lung cancer EGFR mutation with TP53 co-mutation.
- Conditions
- Aumolertinib, Anlotinib, TP53, NSCLC
- Trial name
- NCT05778149
- Testing
- Aumolertinib,Anlotinib
- Volunteers
- 47 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer
To observe the efficacy and safety of hydrochloride anlotinib combined with concurrent radiochemotherapy for patients with FIGO stage IB3 and IIA2-IVA cervical cancer.
- Trial name
- NCT05772377
- Testing
- Hydrochloride anlotinib, cis Platinum/carboplatin, External beam radiotherapy and brachytherapy
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Adjuvant Treatment
Adjuvant Treatment of Digestive Tract Tumors
To evaluate the 3-year Disease-free survival rate(DFSR) of patients with locally advanced gastric cancer and colorectal cancer treated with anlotinib combined with adjuvant chemotherapy.
- Trial name
- ATDTT (NCT05742620)
- Testing
- anlotinib+CAPEOX/SOX
- Volunteers
- 100 people
- Sponsor
- Xijing Hospital
Small Cell Lung Cancer Recurrent
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
The purpose of this study is to assess the efficacy and safety of S1 combination with Anlotinib in patients with small cell lung cancer whose cancer has progression or recurrence after at least one standard chemotherapy.
- Trial name
- NCT03823118
- Testing
- S1/Anlotinib
- Where
- 3 sites in China
- Volunteers
- 48 people
- Sponsor
- Taizhou Hospital
Non Small Cell Lung Cancer
Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment
EGFR T790M gatekeeper mutation accounts for approximately 60% of acquired resistance to the first- or second-generation EGFR-TKI treatment.
- Trial name
- NCT04438902
- Testing
- osimertinib mesylate tablets and anlotinib hydrochloride capsules
- Where
- 2 sites in China
- Volunteers
- 3 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Chondrosarcoma
A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma
There is no standard treatment for chondrosarcoma. Some small sample of studies has shown that anti-angiogenic TKIs show certain activity in the treatment of chondrosarcoma.
- Trial name
- NCT05193188
- Testing
- Anlotinib hydrochloride, PD-1 inhibitor
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Squamous Non-Small Cell Lung Carcinoma
TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
This is Phase 3, randomized, double-blind, parallel controlled study designed to evaluate the Progression Free Survive (PFS) of TQB2450 injection combined with Paclitaxel Injection and Carboplatin Injection Followed by TQB2450…
- Trial name
- NCT05718167
- Testing
- TQB2450, Anlotinib hydrochloride capsule, Tislelizumab injection
- Where
- 4 sites in China
- Volunteers
- 570 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non-Small Cell Lung Cancer
BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer
This is a Phase Ⅰ/Ⅱa, multi-center, open-label study, aiming to evaluate the safety, tolerability, pharmacokinetic (PK), and efficacy of BR790 in combination with anlotinib in adult participants with advanced NSCLC.
- Trial name
- NCT05715398
- Testing
- BR790+anlotinib
- Volunteers
- 90 people
- Sponsor
- Shanghai Gopherwood Biotech Co., Ltd.
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.
According to the definition of National Comprehensive Cancer Network (NCCN), ovarian clear cell carcinoma (OCCC) is a less common subtype of epithelial ovarian cancer (EOC) .
- Trial name
- CC-ANNIE (NCT05130515)
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University